Can new vaccine technology confront drug-resistant bacterial infections?

Drug-resistant microbial infections are a growing problem—could next-generation vaccines be part of the solution? Casey Nevins, Assistant Editor, Vaccine Insights, speaks with Michael Super, Director of ImmunoMaterials, Wyss Institute for Biologically Inspired Engineering, about ciVAXTM, a new broad-spectrum biomaterial vaccine platform targeting bacterial infections and septic shock.

Please enter your email to access content Read now